These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 32250503

  • 1. Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.
    Reding KW, Aragaki AK, Cheng RK, Barac A, Wassertheil-Smoller S, Chubak J, Limacher MC, Hundley WG, D'Agostino R, Vitolins MZ, Brasky TM, Habel LA, Chow EJ, Jackson RD, Chen C, Morgenroth A, Barrington WE, Banegas M, Barnhart M, Chlebowski RT.
    Oncologist; 2020 Aug; 25(8):712-721. PubMed ID: 32250503
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy.
    Wen X, Otoo MN, Tang J, Brothers T, Ward KE, Asal N, Meador KJ.
    JAMA Neurol; 2024 Aug 01; 81(8):866-874. PubMed ID: 38884986
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH.
    Lancet Oncol; 2011 Jan 01; 12(1):65-82. PubMed ID: 21123111
    [Abstract] [Full Text] [Related]

  • 4. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S.
    Drugs; 2020 Jun 01; 80(8):797-811. PubMed ID: 32333236
    [Abstract] [Full Text] [Related]

  • 5. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
    Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, Chalmers J, Teo KK, Pepine CJ, Davis BR, Kjeldsen S, Sundström J, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration.
    Lancet Oncol; 2021 Apr 01; 22(4):558-570. PubMed ID: 33794209
    [Abstract] [Full Text] [Related]

  • 6. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
    Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA.
    Eur J Epidemiol; 2017 Nov 01; 32(11):947-959. PubMed ID: 28752198
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events: a population-based retrospective inception cohort study in the Netherlands.
    Li X, Bijlsma MJ, Bos JHJ, Schuiling-Veninga CCM, Hak E.
    BMJ Open; 2023 Aug 09; 13(8):e068721. PubMed ID: 37558444
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM.
    Cochrane Database Syst Rev; 2015 Jan 11; 1():CD008170. PubMed ID: 25577154
    [Abstract] [Full Text] [Related]

  • 14. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
    Lewinter C, Nielsen TH, Edfors LR, Linde C, Bland JM, LeWinter M, Cleland JGF, Køber L, Braunschweig F, Mansson-Broberg A.
    Eur Heart J; 2022 Jul 14; 43(27):2562-2569. PubMed ID: 34951629
    [Abstract] [Full Text] [Related]

  • 15. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
    Hyman DA, Siebert VR, Birnbaum GD, Alam M, Birnbaum Y.
    Cardiovasc Drugs Ther; 2020 Apr 14; 34(2):215-221. PubMed ID: 32219664
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population-based study.
    Machado MAÁ, de Moura CS, Wang Y, Danieli C, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Clin Hypertens (Greenwich); 2017 Oct 14; 19(10):999-1009. PubMed ID: 28755451
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up.
    Jeong HS, Lim HS, Park HJ, Lee WS, Choi JO, Lee HS, Jo SH, Hong SJ.
    Sci Rep; 2021 Jan 19; 11(1):1783. PubMed ID: 33469103
    [Abstract] [Full Text] [Related]

  • 18. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States.
    Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R.
    J Clin Hypertens (Greenwich); 2007 Sep 19; 9(9):692-700. PubMed ID: 17786070
    [Abstract] [Full Text] [Related]

  • 19. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, Black H, Aragaki A, Trevisan M.
    JAMA; 2004 Dec 15; 292(23):2849-59. PubMed ID: 15598916
    [Abstract] [Full Text] [Related]

  • 20. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R, Michailidis P.
    Clin Ther; 2011 Sep 15; 33(9):1190-203. PubMed ID: 21885126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.